vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and BADGER METER INC (BMI). Click either name above to swap in a different company.
BADGER METER INC is the larger business by last-quarter revenue ($234.1M vs $196.0M, roughly 1.2× Axsome Therapeutics, Inc.). BADGER METER INC runs the higher net margin — 14.3% vs -14.6%, a 28.9% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 14.1%). BADGER METER INC produced more free cash flow last quarter ($50.8M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 9.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Badger Meter Inc. is a leading global provider of flow measurement and control solutions, serving water utilities, industrial, commercial, and residential customer segments. Its core offerings include smart water meters, IoT-enabled usage monitoring systems, and supporting software that help clients track resource consumption, cut waste, and boost operational efficiency, with key markets spanning North America, Europe, and the Asia-Pacific region.
AXSM vs BMI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $234.1M |
| Net Profit | $-28.6M | $33.6M |
| Gross Margin | — | 39.7% |
| Operating Margin | -13.8% | 18.4% |
| Net Margin | -14.6% | 14.3% |
| Revenue YoY | 65.0% | 14.1% |
| Net Profit YoY | 61.9% | 9.3% |
| EPS (diluted) | $-0.55 | $1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $234.1M | ||
| Q3 25 | $171.0M | $222.2M | ||
| Q2 25 | $150.0M | $238.1M | ||
| Q1 25 | $121.5M | $222.2M | ||
| Q4 24 | $118.8M | $205.2M | ||
| Q3 24 | $104.8M | $208.4M | ||
| Q2 24 | $87.2M | $216.7M | ||
| Q1 24 | $75.0M | $196.3M |
| Q4 25 | $-28.6M | $33.6M | ||
| Q3 25 | $-47.2M | $35.1M | ||
| Q2 25 | $-48.0M | $34.6M | ||
| Q1 25 | $-59.4M | $38.4M | ||
| Q4 24 | $-74.9M | $30.7M | ||
| Q3 24 | $-64.6M | $32.0M | ||
| Q2 24 | $-79.3M | $33.1M | ||
| Q1 24 | $-68.4M | $29.1M |
| Q4 25 | — | 39.7% | ||
| Q3 25 | — | 43.1% | ||
| Q2 25 | — | 41.1% | ||
| Q1 25 | — | 42.9% | ||
| Q4 24 | — | 40.3% | ||
| Q3 24 | — | 40.2% | ||
| Q2 24 | — | 39.4% | ||
| Q1 24 | — | 39.3% |
| Q4 25 | -13.8% | 18.4% | ||
| Q3 25 | -27.0% | 20.7% | ||
| Q2 25 | -24.5% | 18.8% | ||
| Q1 25 | -46.9% | 22.2% | ||
| Q4 24 | -61.1% | 19.1% | ||
| Q3 24 | -59.8% | 19.5% | ||
| Q2 24 | -89.5% | 19.2% | ||
| Q1 24 | -89.7% | 18.6% |
| Q4 25 | -14.6% | 14.3% | ||
| Q3 25 | -27.6% | 15.8% | ||
| Q2 25 | -32.0% | 14.5% | ||
| Q1 25 | -48.9% | 17.3% | ||
| Q4 24 | -63.1% | 15.0% | ||
| Q3 24 | -61.7% | 15.4% | ||
| Q2 24 | -91.0% | 15.3% | ||
| Q1 24 | -91.1% | 14.8% |
| Q4 25 | $-0.55 | $1.13 | ||
| Q3 25 | $-0.94 | $1.19 | ||
| Q2 25 | $-0.97 | $1.17 | ||
| Q1 25 | $-1.22 | $1.30 | ||
| Q4 24 | $-1.54 | $1.04 | ||
| Q3 24 | $-1.34 | $1.08 | ||
| Q2 24 | $-1.67 | $1.12 | ||
| Q1 24 | $-1.44 | $0.99 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $713.3M |
| Total Assets | $689.8M | $973.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | $88.3M | $713.3M | ||
| Q3 25 | $73.7M | $702.5M | ||
| Q2 25 | $73.1M | $677.6M | ||
| Q1 25 | $53.2M | $641.7M | ||
| Q4 24 | $57.0M | $606.2M | ||
| Q3 24 | $92.9M | $591.2M | ||
| Q2 24 | $102.9M | $563.1M | ||
| Q1 24 | $144.0M | $535.6M |
| Q4 25 | $689.8M | $973.6M | ||
| Q3 25 | $669.3M | $978.3M | ||
| Q2 25 | $639.8M | $936.4M | ||
| Q1 25 | $596.7M | $899.6M | ||
| Q4 24 | $568.5M | $816.4M | ||
| Q3 24 | $561.5M | $802.9M | ||
| Q2 24 | $548.2M | $781.3M | ||
| Q1 24 | $545.7M | $743.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $54.8M |
| Free Cash FlowOCF − Capex | $-18.7M | $50.8M |
| FCF MarginFCF / Revenue | -9.6% | 21.7% |
| Capex IntensityCapex / Revenue | 0.0% | 1.7% |
| Cash ConversionOCF / Net Profit | — | 1.63× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $169.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $54.8M | ||
| Q3 25 | $1.0M | $51.3M | ||
| Q2 25 | $-32.4M | $44.6M | ||
| Q1 25 | $-43.4M | $33.0M | ||
| Q4 24 | $-26.2M | $52.1M | ||
| Q3 24 | $-18.6M | $45.1M | ||
| Q2 24 | $-30.1M | $36.4M | ||
| Q1 24 | $-53.5M | $21.5M |
| Q4 25 | $-18.7M | $50.8M | ||
| Q3 25 | $988.0K | $48.2M | ||
| Q2 25 | $-32.4M | $40.6M | ||
| Q1 25 | $-43.7M | $30.1M | ||
| Q4 24 | $-26.2M | $47.4M | ||
| Q3 24 | $-18.7M | $42.0M | ||
| Q2 24 | $-30.2M | $34.1M | ||
| Q1 24 | $-53.6M | $18.8M |
| Q4 25 | -9.6% | 21.7% | ||
| Q3 25 | 0.6% | 21.7% | ||
| Q2 25 | -21.6% | 17.1% | ||
| Q1 25 | -36.0% | 13.5% | ||
| Q4 24 | -22.1% | 23.1% | ||
| Q3 24 | -17.9% | 20.1% | ||
| Q2 24 | -34.6% | 15.7% | ||
| Q1 24 | -71.4% | 9.6% |
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.3% | 1.3% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.1% | 1.5% | ||
| Q2 24 | 0.1% | 1.1% | ||
| Q1 24 | 0.1% | 1.4% |
| Q4 25 | — | 1.63× | ||
| Q3 25 | — | 1.46× | ||
| Q2 25 | — | 1.29× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 1.70× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 0.74× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
BMI
| Transferred At Point In Time | $198.6M | 85% |
| Transferred Over Time | $22.1M | 9% |
| Other | $13.4M | 6% |
